Overexpression of KMT9α is associated with poor outcome in cholangiocarcinoma patients

Abstract Purpose The newly discovered histone methyltransferase KMT9 serves as an epigenetic regulator of carcinogenesis in various cancer entities. For the first time, we investigated the presence of KMT9α in cholangiocarcinoma, the association with histologic subtypes, and its impact on survival....

Popoln opis

Bibliografske podrobnosti

Principais autores:	Maximilian N. Kinzler, Eric Metzger, Rebecca Schulz, Katrin Bankov, Anna Ramos-Triguero, Falko Schulze, Steffen Gretser, Nada Abedin, Armin Wiegering, Stefan Zeuzem, Dirk Walter, Henning Reis, Roland Schüle, Peter J. Wild
Format:	Artigo
Jezik:	Inglês
Izdano:	Springer 2025-05-01
Serija:	Journal of Cancer Research and Clinical Oncology
Teme:	Biomarker Cholangiocarcinoma Surgical oncology Lysine methyltransferase 9 KMT9α
Online dostop:	https://doi.org/10.1007/s00432-025-06214-w
Oznake:	Označite Brez oznak, prvi označite!